Literature DB >> 32910949

Drug Metabolites Potently Inhibit Renal Organic Anion Transporters, OAT1 and OAT3.

Ling Zou1, Pär Matsson2, Adrian Stecula1, Huy X Ngo1, Arik A Zur1, Kathleen M Giacomini3.   

Abstract

Human OAT1 and OAT3 play major roles in renal drug elimination and drug-drug interactions. However, there is little information on the interactions of drug metabolites with transporters. The goal of this study was to characterize the interactions of drug metabolites with OAT1 and OAT3 and compare their potencies of inhibition with those of their corresponding parent drugs. Using HEK293 cells stably transfected with OAT1 and OAT3, 25 drug metabolites and their corresponding parent drugs were screened for inhibitory effects on OAT1-and OAT3-mediated 6-carboxyfluorescein uptake at a screening concentration of 200 μM for all but 3 compounds. 20 and 24 drug metabolites were identified as inhibitors (inhibition > 50%) of OAT1 and OAT3, respectively. Seven drug metabolites were potent inhibitors of either or both OAT1 and OAT3 with Ki values less than 1 μM. 22 metabolites were more potent inhibitors of OAT3 than OAT1. Importantly, one drug and four metabolites were predicted to inhibit OAT3 at unbound plasma concentrations achieved clinically (Cmax,u/Ki values ≥ 0.1). In conclusion, our study highlights the potential interactions of drug metabolites with OAT1 and OAT3 at clinically relevant concentrations, suggesting that drug metabolites may modulate therapeutic and adverse drug response by inhibiting renal drug transporters.
Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug-drug interaction(s); Metabolism; Organic anion transporters (OAT)

Mesh:

Substances:

Year:  2020        PMID: 32910949      PMCID: PMC8177813          DOI: 10.1016/j.xphs.2020.09.004

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.784


  28 in total

Review 1.  Understanding the transport properties of metabolites: case studies and considerations for drug development.

Authors:  Maciej J Zamek-Gliszczynski; Xiaoyan Chu; Joseph W Polli; Mary F Paine; Aleksandra Galetin
Journal:  Drug Metab Dispos       Date:  2013-12-17       Impact factor: 3.922

2.  Transporters in Drug Development: Scientific and Regulatory Considerations.

Authors:  Lei Zhang; Shiew-Mei Huang; Kellie Reynolds; Rajanikanth Madabushi; Issam Zineh
Journal:  Clin Pharmacol Ther       Date:  2018-09-30       Impact factor: 6.875

Review 3.  Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.

Authors:  Maciej J Zamek-Gliszczynski; Mitchell E Taub; Paresh P Chothe; Xiaoyan Chu; Kathleen M Giacomini; Richard B Kim; Adrian S Ray; Sophie L Stocker; Jashvant D Unadkat; Matthias B Wittwer; Cindy Xia; Sook-Wah Yee; Lei Zhang; Yan Zhang
Journal:  Clin Pharmacol Ther       Date:  2018-08-08       Impact factor: 6.875

4.  The Need for Speed-Kinetic Limits of Drug Transporters.

Authors:  Pär Matsson; Patrik Lundquist; Per Artursson
Journal:  Trends Pharmacol Sci       Date:  2016-02-24       Impact factor: 14.819

5.  Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1).

Authors:  Tomoe Fujita; Chaline Brown; Elaine J Carlson; Travis Taylor; Melanie de la Cruz; Susan J Johns; Doug Stryke; Michiko Kawamoto; Kazumi Fujita; Richard Castro; Chung-Wen Chen; Emil T Lin; Claire M Brett; Esteban Gonzalez Burchard; Thomas E Ferrin; Conrad C Huang; Maya K Leabman; Kathleen M Giacomini
Journal:  Pharmacogenet Genomics       Date:  2005-04       Impact factor: 2.089

6.  A Comparative Analysis of Cytochrome P450 Activities in Paired Liver and Small Intestinal Samples from Patients with Obesity.

Authors:  Veronica Krogstad; Alexandra Peric; Ida Robertsen; Marianne K Kringen; Christine Wegler; Philip Carlo Angeles; Jøran Hjelmesæth; Cecilia Karlsson; Shalini Andersson; Per Artursson; Anders Åsberg; Tommy B Andersson; Hege Christensen
Journal:  Drug Metab Dispos       Date:  2019-11-04       Impact factor: 3.922

7.  Differences in the substrate binding regions of renal organic anion transporters 1 (OAT1) and 3 (OAT3).

Authors:  Bethzaida Astorga; Theresa M Wunz; Mark Morales; Stephen H Wright; Ryan M Pelis
Journal:  Am J Physiol Renal Physiol       Date:  2011-05-04

8.  Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices.

Authors:  Yoshitane Nozaki; Hiroyuki Kusuhara; Tsunenori Kondo; Masahiro Iwaki; Yoshiyuki Shiroyanagi; Hideki Nakayama; Shigeru Horita; Hayakazu Nakazawa; Teruo Okano; Yuichi Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  2007-06-19       Impact factor: 4.030

9.  Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8).

Authors:  Sook Wah Yee; Anh Nguyet Nguyen; Chaline Brown; Radojka M Savic; Youcai Zhang; Richard A Castro; Cheryl D Cropp; Ji Ha Choi; Diment Singh; Harunobu Tahara; Sophie L Stocker; Yong Huang; Claire M Brett; Kathleen M Giacomini
Journal:  J Pharm Sci       Date:  2013-05-06       Impact factor: 3.534

10.  Unique metabolite preferences of the drug transporters OAT1 and OAT3 analyzed by machine learning.

Authors:  Anisha K Nigam; Julia G Li; Kaustubh Lall; Da Shi; Kevin T Bush; Vibha Bhatnagar; Ruben Abagyan; Sanjay K Nigam
Journal:  J Biol Chem       Date:  2020-01-02       Impact factor: 5.157

View more
  4 in total

1.  Emerging Roles of the Human Solute Carrier 22 Family.

Authors:  Sook Wah Yee; Kathleen M Giacomini
Journal:  Drug Metab Dispos       Date:  2021-12-17       Impact factor: 3.579

2.  Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data.

Authors:  Sook Wah Yee; Bianca Vora; Tomiko Oskotsky; Ling Zou; Sebastian Jakobsen; Osatohanmwen J Enogieru; Megan L Koleske; Idit Kosti; Mattias Rödin; Marina Sirota; Kathleen M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2021-05-03       Impact factor: 6.875

Review 3.  The Role of Uptake and Efflux Transporters in the Disposition of Glucuronide and Sulfate Conjugates.

Authors:  Erkka Järvinen; Feng Deng; Wilma Kiander; Alli Sinokki; Heidi Kidron; Noora Sjöstedt
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

Review 4.  The Interplay between Uremic Toxins and Albumin, Membrane Transporters and Drug Interaction.

Authors:  Regiane Stafim da Cunha; Carolina Amaral Bueno Azevedo; Carlos Alexandre Falconi; Fernanda Fogaça Ruiz; Sophie Liabeuf; Marcela Sorelli Carneiro-Ramos; Andréa Emilia Marques Stinghen
Journal:  Toxins (Basel)       Date:  2022-02-26       Impact factor: 4.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.